FY 18 consolidated eps was 30. Standalone was 20.
I expect FY 19 consolidated eps to be in range of 38-40 on a conservative basis. I dont know how Mawag is going to perform but according to management commentary that too is doing well. Standalone results till q2 fy 19 have been good and have shown nearly 50% growth in profits.
Based on expected FY 19 earnings valuations come down to below 30 PE.
The good thing about playing this theme of capex in speciality, agrochem and pharma is that one is not exposed to vagaries of individual molecule prices and any USFDA or other regulatory agency actions.